NCT03750071 - VXM01 Plus Avelumab Combination Study in Progressive Glioblastoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 21, 2018

Primary Completion Date

December 31, 2021

Study Completion Date

December 31, 2022

Conditions

Recurrent Glioblastoma

Interventions

BIOLOGICAL

VXM01

Ty21a transformed with a eukaryotic VEGFR-2 Expression Plasmid

BIOLOGICAL

Avelumab

Monoclonal anti-PD-L1 Antibody

Trial Locations (2)

Neurology Clinic, Mannheim

Neurology Clinic and National Center for Tumor Diseases, Heidelberg